ISSN: 2161-0495
+44 1478 350008
A. Salmi
Tramadol® (analgesic of the landing 2) is a centrally acting analgesic with a dual mode of action. Its analgesic efficacy is attributed to its partial affinity for the (μ) mu-opiate receptor and its inhibition of noradrenaline and serotonin reuptake. Acting in a synergistic manner and being more efficacious, Tramadol® is used worldwide for the treatment of moderate to severe acute or chronic pain. If psychotropics are not an exceptional one because of SIADH (syndrome Inappropriate secretion of antidiuretic hormone), analgesics are not usually. This is the case of Tramadol®. We report on this observation the case of a 22 year old patient hospitalized for poisoning Tramadol®, having presented, hyponatremia, hypoglycemia, rhabdomyolyse and left cardiac decompensation.